Amsterdam, the Netherlands - 12 November 2015 - Our portfolio company Curetis N.V., a developer of advanced molecular diagnostic assays for severe infectious diseases in hospitalized patients, raised € 40 million in an initial public offering (IPO) through a listing in Euronext Amsterdam and Euronext Brussels. LSP has led the Series A financing of Curetis in 2009 and supported the company in further financings in subsequent years and in the IPO process. For LSP’s Health Economics Fund it is the first of its portfolio companies that becomes listed on the stock market. We are very happy that our portfolio company Curetis is one of a very few European medtech companies that successfully achieved a listing on Euronext this year.  A version of the company’s press release can be found here.

 

About LSP

LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com

 

We are looking forward to keeping you informed about further news.